This Phase 2 study is testing if a medicine called Pulmozyme (recombinant human deoxyribonuclease or rh-DNase) can help reduce deaths in people with COVID-19 who are experiencing breathing problems. Participants will receive either Pulmozyme or a placebo (an inactive substance like salt water) through a nebulizer (a device that turns liquid medicine into a mist to be inhaled) once a day for five days. The study is looking to see if Pulmozyme is safe and if it lowers the number of deaths 28 days after starting treatment, and how well people respond to the treatment after 5 days. You might be able to join if you are 18 or older, have COVID-19, and are on high-flow oxygen or a breathing machine. The current status of this study is unclear, and it plans to enroll 44 people.

Study design

This is a Phase 2 randomized, placebo-controlled study, meaning participants are randomly assigned to receive either the study drug or a placebo. It plans to include 44 participants.

What's involved

Participants will receive either Pulmozyme or a placebo through a nebulizer once every 24 hours for five consecutive days, for a total of five doses.

Compensation

Not stated in the trial record.

Follow-up

The study will measure mortality at 28 days after enrollment and systemic therapeutic response at 5 days after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.